As transactions increasingly cross international borders, O’Melveny is well equipped to help clients successfully negotiate the issues and complexities that inevitably arise. We handle inbound and outbound tax issues in matters that range from financings to investment funds to joint ventures and mergers and acquisitions.
Working seamlessly with teams across O’Melveny’s broad transactions practice, we leverage our thorough knowledge of complex tax laws to devise strategic and pragmatic solutions tailored to our clients’ business priorities.
One of the few international law firms with our own US, UK, and Chinese international tax capabilities, we also have strong working relationships with leading independent law firms across Europe, Asia, and in many other geographies to assist our clients in structuring and executing transactions in jurisdictions where we do not have offices. In such cases, we act as co-counsel or coordinate the work according to client preference and the particular needs of the transaction.
Lionsgate Entertainment Corp.O’Melveny represented Lionsgate in its multiyear slate co-financing deal with Hunan TV & Broadcast Intermediary Co. Ltd. in reportedly the biggest investment in Hollywood by a Chinese company to date. Read
Montage Technology Group LimitedO’Melveny represented Montage Technology Group Limited, a global fabless provider of analog and mixed-signal semiconductor solutions based in China, in connection with a merger agreement with Shanghai Pudong Science and Technology Investment Co., Ltd. in a US$693 million going private transaction. Read
- 7 Days Group Holdings Limited
- Axiom Asia Private Capital
- Canada Pension Plan Investment Board
- China Investment Corporation
- Coller Investment Management Limited
- GIC Private Limited
- Goldman Sachs & Co.
- Helios Investment Group
- Honeywell International Inc.
- Korea Investment Corporation
- Lions Gate Entertainment Corp.
- Montage Technology Group Limited
- Safe Investment Company Limited
- Temasek Holding (Private) Limited
- UBS AG
- WuXi PharmaTech
Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.
Alerts and Publications
December 29, 2022New Guidance on FIRPTA’s Application to REITs, RICs, Foreign Governments, and Foreign Pension Funds
Our professionals are regularly recognized as leading advisors for tax matters in publications such as International Tax Review, China Law and Practice, and Chambers UK.